1.8929
Immuron Limited Adr stock is traded at $1.8929, with a volume of 1,526.
It is up +10.70% in the last 24 hours and up +4.06% over the past month.
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.
See More
Previous Close:
$1.71
Open:
$1.8929
24h Volume:
1,526
Relative Volume:
0.11
Market Cap:
$10.43M
Revenue:
$2.35M
Net Income/Loss:
$-2.56M
P/E Ratio:
-4.2243
EPS:
-0.4481
Net Cash Flow:
-
1W Performance:
+14.72%
1M Performance:
+4.06%
6M Performance:
-3.91%
1Y Performance:
-21.46%
Immuron Limited Adr Stock (IMRN) Company Profile
Compare IMRN with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
IMRN
Immuron Limited Adr
|
1.8929 | 10.43M | 2.35M | -2.56M | 0 | -0.4481 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Immuron Limited Adr Stock (IMRN) Latest News
Immuron and Calmino join up to treat Irritable Bowel Syndrome (IBS) - Markets Insider
Immuron: Targeted oral antibodies to treat infectious diseases - Innovation News Network
Immuron Travelan® continued strong sales growth - GlobeNewswire Inc.
Immuron to Present at Q4 Virtual Investor Summit: Gut Disease Pipeline Showcase | IMRN Stock News - StockTitan
Immuron Travelan® continued strong sales growth - Quantisnow
NMRC Reports Results for Campylobacter Controlled Human Infection Model Study - GlobeNewswire
Immuron: US FDA provides favourable feedback ahead of investigational new drug application for IMM-529 - Proactive Investors Australia
Immuron Plans Phase 2 Trial for IMM-529 following FDA review - GlobeNewswire
Immuron requests pre-IND meeting for IMM-529 with FDA filing - Yahoo Finance
Why PriceSmart Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket - Markets Insider
U.S. shares higher at close of trade; Dow Jones Industrial Average up 0.34% - Investing.com UK
Immuron Limited Announces Participation in the LD Micro Invitational XIII - The Kingston Whig-Standard
Immuron US DoD Naval Medical Research Center responds to - GlobeNewswire
Immuron Surges On U.S. DoD Funding For Travelan Research By Investing.com - Investing.com Nigeria
Immuron US DoD Naval Medical Research Center Receives feedback on IND Application for New Campylobacter ETEC Therapeutic - StockTitan
Immuron LimitedADR Shares Close the Week 61.5% HigherWeekly Wrap - Nasdaq
IMRNImmuron Ltd Latest Stock News & Market Updates - Stock Titan
Immuron’s Technology Platform of Treatments in the Age of the Coronavirus Outbreak - GlobeNewswire
Immuron Limited Trade Ideas — NASDAQ:IMRN - TradingView
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.33% - Investing.com
Immuron Limited Issues Correction to Misleading Halt Announcement Headline - GlobeNewswire
IMC Stock Price and Chart — ASX:IMC - TradingView
Pharma & Biotech - Proactive Investors USA
Immuron Limited Adr Stock (IMRN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):